A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of New-Onset Symptomatic Atrial Fibrillation to Sinus Rhythm (RESTORE-1)
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: INCARDA THERAPEUTICS, INC
- Phase: III
- Execution start: 28/11/2022
- End of execution: 30/08/2023
- IP: LUIS TERCEDOR SANCHEZ